Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Current Leases (2016 - 2025)

Zevra Therapeutics' Current Leases history spans 11 years, with the latest figure at $419000.0 for Q4 2025.

  • For Q4 2025, Current Leases changed 0.24% year-over-year to $419000.0; the TTM value through Dec 2025 reached $419000.0, changed 0.24%, while the annual FY2025 figure was $419000.0, 0.24% changed from the prior year.
  • Current Leases reached $419000.0 in Q4 2025 per ZVRA's latest filing, down from $441000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $596000.0 in Q2 2024 to a low of $336000.0 in Q1 2021.
  • Average Current Leases over 5 years is $458315.8, with a median of $456000.0 recorded in 2023.
  • Peak YoY movement for Current Leases: soared 35.82% in 2022, then dropped 22.65% in 2024.
  • A 5-year view of Current Leases shows it stood at $356000.0 in 2021, then skyrocketed by 34.83% to $480000.0 in 2022, then increased by 13.12% to $543000.0 in 2023, then dropped by 22.65% to $420000.0 in 2024, then decreased by 0.24% to $419000.0 in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Current Leases are $419000.0 (Q4 2025), $441000.0 (Q3 2025), and $525000.0 (Q2 2025).